4.1 Article

Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, Recommendations of the COPD Foundation

Journal

Publisher

TAYLOR & FRANCIS INC
DOI: 10.3109/15412555.2013.801309

Keywords

COPD; spirometry; diagnosis; treatment

Funding

  1. GlaxoSmithKline plc
  2. Novartis Pharmaceuticals
  3. Pfizer Inc.
  4. Boehringer-Ingelheim
  5. AstraZeneca PLC
  6. Forest Laboratories Inc.
  7. Merck
  8. Creative Educational Concepts
  9. AstraZeneca
  10. Biomarck
  11. Centocor
  12. Mpex
  13. Nabi
  14. Novartis
  15. Otsuka

Ask authors/readers for more resources

The increasing number of treatment options for managing patients with chronic obstructive pulmonary disease (COPD) promises to improve the outcomes for COPD patients. However, determining which treatments are appropriate for individual patients has become increasingly complex. The COPD Foundation Guide for Diagnosis and Management of COPD was developed to be a practical, easy to use tool for clinicians. The Guide includes specific recommendations for diagnostic studies and treatments based on specific diagnostic criteria. This manuscript describes the rationale for the development of the Guide, the process used, the rationale for the specific recommendations and the plans for further development. The current recommendations of the COPD Foundation have been summarized in the form of Pocket Cards, which may be obtained from the Foundation at no charge (1-866-316-COPD (2673), www.copdfoundation.org).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available